Table 1 Baseline characteristic of patients
| Characteristics |
Total (N = 320) |
PI base (n = 143) |
NNRTI base (n = 177) | p-value* |
|---|---|---|---|---|
| Age, years, median (IQR) | 46 (41–50) | 46 (41–50) | 46 (41–50) | 0.45 |
| Male sex, n (%) | 178 (55.63) | 69 (48.25) | 109 (61.58) | 0.02 |
| Baseline body weight, Kg, median (IQR) | 61 (53–69) | 61 (54–69) | 61 (52–69) | 0.83 |
| Duration of HIV infection, year, median (IQR) | 14 (11–18) | 14 (11–19) | 15 (11–18) | 0.57 |
| Duration of ART, years, median (IQR) | 12 (8–16) | 12 (9–17) | 12 (5–16) | 0.13 |
| Duration of virological suppression, years, median (IQR) | 8.6 (3.7–11.1) | 8.6 (4.0–11.0) | 8.7 (3.5–11.3) | 0.90 |
| Nadir CD4+ T-cell count, cells/μL, median (IQR) | 210 (121–294) | 203 (108–275) | 221 (136–304) | 0.16 |
| Baseline CD4+ T-cell count, cells/μL, median (IQR) | 674 (522–851) | 696 (541–870) | 649 (502–814) | 0.09 |
| Highest viral load before starting ART (n, %) | 0.62 | |||
| < 100,000 copies/mL | 151 (54.71) | 71 (56.35) | 80 (53.33) | |
| ≥ 100,000 copies/mL | 125 (45.29) | 55 (43.65) | 70 (46.67) | |
| HBsAg positive (n, %) | 37 (11.78) | 11 (7.80) | 26 (15.03) | 0.048 |
| Anti-HCV positive (n, %) | 13 (4.08) | 9 (6.34) | 4 (2.26) | 0.09 |
| Previous treatment regimens, n (%) | N/A | |||
| EFV | 158 (49.38) | 0 (0) | 158 (89.27) | |
| NVP | 19 (5.94) | 0 (0) | 19 (10.73) | |
| SQV/r | 24 (7.50) | 24 (16.78) | 0 (0) | |
| LPV/r | 51 (15.94) | 51 (35.66) | 0 (0) | |
| ATV/r | 62 (19.38) | 62 (43.36) | 0 (0) | |
| DRV/r | 6 (1.88) | 6 (4.20) | 0 (0) | |
| Currently on treatment with TDF (n, %) | 305 (95.31) | 137 (95.8) | 168 (94.92) | 0.71 |
| Baseline laboratory | ||||
| Chol (mg/dL), median (IQR) | 210 (182–239) | 205 (182–242) | 211 (182–237) | 0.90 |
| TG (mg/dL), median (IQR) | 138 (94–206) | 163 (103–224) | 127 (85–192) | 0.002 |
| HDL (mg/dL), median (IQR) | 46 (38–53) | 43 (38–51) | 47 (39–55) | 0.01 |
| LDL (mg/dL), median (IQR) | 131 (107–153) | 129 (106–153) | 132 (107–154) | 0.51 |
| ALT (mg/dL), median (IQR) | 26 (19–39) | 24 (19–37) | 28 (21–41) | 0.02 |
| eGFR(CKD-EPI) (mL/min/1.73 m2), median (IQR) | 101.35 (88.02–109.19) | 99.4 (84.1–107.99) | 102.62 (92.66–110.72) | 0.01 |
| Creatinine (mg/dL), median (IQR) | 0.83 (0.72–0.96) | 0.84 (0.70–0.97) | 0.83 (0.72–0.95) | 0.74 |
| Reason for switching to RPV | < 0.001 | |||
| CNS toxicity | 89 (28.25) | 3 (2.11) | 86 (49.71) | |
| Simplify regimen | 128 (40.63) | 108 (76.06) | 20 (11.56) | |
| Dyslipidemia | 70 (22.22) | 21 (14.79) | 49 (28.32) | |
| Gynecomastia form EFV | 5 (1.59) | 0 (0) | 5 (2.89) | |
| EFV induce hepatitis | 2 (0.63) | 0 (0) | 2 (1.16) | |
| LPV/r GI side effect | 4 (1.27) | 4 (2.82) | 0 (0) | |
| Lipodystrophy | 9 (2.86) | 0 (0) | 9 (5.20) | |
| ATV induce gall stone | 1 (0.32) | 1 (0.70) | 0 (0) | |
| Other | 7 (2.22) | 5 (3.52) | 2 (1.16) |